Recombinant Human HMGB1, CF Summary
| Details of Functionality |
Measured in a competitive binding assay. When recombinant human RAGE Fc Chimera is immobilized at 2 µg/mL (100 µL/well), Recombinant Human HMGB1/HMG‑1 inhibits 50% binding of biotinylated recombinant human HMGB1 (0.25 µg/mL) at the concentration range of 0.35-1.4 µg/mL. |
| Source |
Mouse myeloma cell line, NS0-derived human HMGB1/HMG-1 protein Met1-Glu215 Accession # P09429.3 |
| Accession # |
|
| Protein/Peptide Type |
Recombinant Proteins |
| Purity |
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain |
| Endotoxin Note |
<0.10 EU per 1 μg of the protein by the LAL method. |
Applications/Dilutions
| Dilutions |
|
| Theoretical MW |
24.9 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
| SDS-PAGE |
30-36 kDa, reducing conditions |
| Publications |
Read Publications using 1690-HM in the following applications:
|
|
Packaging, Storage & Formulations
| Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 6 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after opening.
- 3 months, -20 to -70 °C under sterile conditions after opening.
|
| Buffer |
Supplied as a 0.2 μm filtered solution in PBS, EDTA and DTT. |
| Purity |
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain |
| Reconstitution Instructions |
It is recommended that sterile PBS be added to the vial to prepare a working stock solution of no less than 100 μg/mL. The carrier-free protein should be used immediately upon reconstitution to avoid losses in activity due to non-specific binding to the inside surface of the vial. For long term storage as a dilute solution, a carrier protein (e.g. 0.1% HSA or BSA) should be added to the vial. |
Notes
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Recombinant Human HMGB1, CF
Background
High-mobility Group Box 1 protein (HMGB1), also known as HMG1 or Amphoterin, is a member of the high mobility group box family of non-histone chromosomal proteins (1-3). Human HMGB1 is expressed as a 25 kDa single chain protein containing two globular positively charged DNA-binding domains (HMG boxes A and B) and a negatively charged C-terminal region that contains only Asp and Glu residues (4, 5). Posttranslational modification of HMBG1, including acetylation, phosphorylation, and methylation, affects HMBG1 localization, receptor interactions, and bioactivity (3). An intramolecular disulfide bond between Cys23 and Cys45 as well as the presence of the unpaired Cys106 thiol are critical for HMGB1-induced pro-inflammatory TNF-alpha secretion (2, 6). Alternatively, fully reduced HMGB1 acts as a potent chemoattractant for neutrophils and monocytes (7). HMGB1 can be localized to the nucleus or cytoplasm and can also be secreted despite its lack of a signal peptide (2). HMGB1 binds DNA in a non-sequence specific manner and may act as a structural cofactor during gene transcription (8). Acetylation of HMGB1 results in its cytoplasmic localization and eventual secretion (9). HMGB1 can be secreted by multiple cell types, and it is also released upon cell necrosis, apoptosis, and pyroptosis (2, 3). HMBG1 is widely recognized as a multifunctional alarmin that stimulates inflammation upon sterile or infectious insult. Receptors for HMGB1 include TLR2, TLR4, TLR9, Syndecan-3, Siglec-10, Integrin alpha M beta 2, CXCR4, TIM-3, and RAGE (1, 2). It is implicated in the pathogenesis of a broad range of diseases including atherosclerosis, sepsis, cancer, neurodegenerative diseases, and autoimmunity (3, 10-13).
- Yanai, H. et al. (2012) Trends Immunol. 33:633.
- Yang, H. et al. (2013) J. Leukoc. Biol. 93:865.
- Harris, H.E. et al. (2012) Nat. Rev. Rheumatol. 8:195.
- Degryse, B. and M. de Virgilio (2003) FEBS Lett. 553:11.
- Wen, L. et al. (1989) Nucleic Acids Res. 17:1197.
- Yang, H. et al. (2012) Mol. Med. 18:250.
- Venereau, E. et al. (2012) J. Exp. Med. 209:1519.
- Bianchi, M.E. and A. Agresti (2005) Curr. Opin. Genet. Dev. 15:496.
- Bonaldi, T. et al. (2003) EMBO J. 22:5551.
- Diener, K.R. et al. (2013) Immunol. Cell Biol. 91:443.
- Fang, P. et al. (2012) Mol. Neurobiol. 45:499.
- de Souza, A.W. et al. (2012) Autoimmun. Rev. 11:909.
- Bae, J.S. (2012) Arch. Pharm. Res. 35:1511.
Customers Who Viewed This Item Also Viewed...
Species: Hu
Applications: BA
Species: Bv, Hu, Ma, Mu, Po, Rt
Applications: B/N, ChIP, CyTOF-ready, DB, Dual ISH-IHC, ELISA(Cap), ELISA, Flow-CS, Flow-IC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, In vitro, KD, KO, PAGE, Simple Western, WB
Species: Mu
Applications: ELISA
Species: Hu, Mu, Rt
Applications: ELISA, IHC, IHC-P, WB
Species: Hu
Applications: ELISA
Species: Ca, Hu, Mu, Rb, Rt
Applications: B/N, DB, ELISA, Flow-CS, Flow, Func, ICC/IF, IP, In vitro, WB
Species: Hu, Mu, Rt
Applications: ChIP, ELISA, ICC/IF, IHC, IHC-P, IP, WB
Species: Mu
Applications: ELISA
Species: Hu, Mu, Rt
Applications: IHC, KO, WB
Species: Hu, Rb, Rt
Applications: Flow, IHC, IHC-P, KO, Simple Western, WB
Species: Hu
Applications: ELISA, AP, PA, WB
Species: Hu, Mu
Applications: ICC/IF, WB
Species: Hu
Applications: IHC, IHC-P, IP, WB
Species: Hu, Mu, Rt
Applications: ELISA
Species: Hu, Mu
Applications: ICC/IF, IHC, IHC-P, WB
Species: Bv, Hu
Applications: CyTOF-ready, Flow, IP
Species: Hu
Applications: ELISA
Species: Hu
Applications: ICC/IF, IP, WB
Species: Hu, Mu
Applications: Dual ISH-IHC, ICC, IHC, Simple Western, WB
Species: Hu
Applications: Binding Activity
FAQs for HMGB1/HMG-1 (1690-HM) (0)